A similar ADC HKT288 that used a DM4 payload with anti-CDH6 monoclonal was discontinued over inflammatory and neurological adverse events. Would the adverse events be tied to targeting CDH6 or to payload toxicities?

More Emily Benesh's questions See All
Similar questions and discussions